Michelle R. Ryan Sells 2,800 Shares of Catalent, Inc. (NYSE:CTLT) Stock

Catalent, Inc. (NYSE:CTLT) Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Catalent Stock Performance

NYSE:CTLT traded up $0.19 on Friday, reaching $59.10. 210,130 shares of the company’s stock traded hands, compared to its average volume of 2,029,098. The stock has a 50-day simple moving average of $59.89 and a 200-day simple moving average of $58.16. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $61.20.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the company earned ($0.10) EPS. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, research analysts predict that Catalent, Inc. will post 0.84 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its stake in Catalent by 14.9% in the first quarter. Russell Investments Group Ltd. now owns 27,636 shares of the company’s stock valued at $1,560,000 after purchasing an additional 3,578 shares during the last quarter. ProShare Advisors LLC grew its stake in Catalent by 15.3% during the 1st quarter. ProShare Advisors LLC now owns 28,763 shares of the company’s stock valued at $1,624,000 after purchasing an additional 3,814 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Catalent by 2,792.9% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock worth $29,150,000 after purchasing an additional 498,540 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Catalent by 27.9% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 218,586 shares of the company’s stock worth $12,339,000 after purchasing an additional 47,739 shares during the period. Finally, Blair William & Co. IL boosted its position in Catalent by 3.0% in the first quarter. Blair William & Co. IL now owns 41,998 shares of the company’s stock valued at $2,371,000 after buying an additional 1,220 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Finally, StockNews.com raised Catalent from a “sell” rating to a “hold” rating in a report on Thursday. Nine investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.